Tracer library / [111In]DOTA-TRK-950
[111In]DOTA-TRK-950
Also written as [In-111]In-DOTA-TRK-950
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- SPECT
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- Targets CAPRIN-1, a cancer-specific cell surface antigen, via the anti-CAPRIN-1 humanized monoclonal antibody TRK-950 PMID 40473914
- Clinical application
- Tumor imaging (SPECT/CT) and radioimmunotherapy of CAPRIN-1-expressing solid tumors, evaluated in preclinical proof-of-concept study PMID 40473914
- Theranostic pair
- [177Lu]Lu-DOTA-TRK-950
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | ≥ 95% | TRK-950-DOTA | 40473914 2025 J Cancer Res Clin Oncol Radiolabeling of TRK-950-DOTA with 111In was performed using a method modified slightly based on previously described |
Need this precursor?We can point you to suppliers for [111In]DOTA-TRK-950, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40473914. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40473914: 'Radiolabeling of TRK-950-DOTA with 111In'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: In-111 agent whose theranostic partner lu177-dotatrk950 carries the therapy isotope Lu-177: this is the imaging half of the pair. Linked articles: PMID 40473914.